Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Current Health Sciences Journal
|
April 30, 2014
A comparison of endoscopic ultrasound guided biopsy and positron emission tomography with integrated computed tomography in lung cancer staging
S S Larsen, P Vilmann, K Krasnik, et al.
British Journal of Cancer
|
July 1, 2010
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
U Lassen, L R Molife, M Sorensen, et al.
Investigational New Drugs
|
April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C Even, U Lassen, J Merchan, et al.
Cancer Chemotherapy and Pharmacology
|
December 1, 2012
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours
U Lassen, W H Miller, S Hotte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
C Massard, A Azaro, J-C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2025
Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting
L Belcaid, M Højgaard, I Tuxen, et al.
ESMO Open
|
November 6, 2025
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium
S F Haj Mohammad, H van der Pol, E Vrdoljak, et al.
ESMO Open
|
May 13, 2026
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors
U Lassen, E M J van Brummelen, I Melero, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Current Health Sciences Journal
|
April 30, 2014
A comparison of endoscopic ultrasound guided biopsy and positron emission tomography with integrated computed tomography in lung cancer staging
S S Larsen, P Vilmann, K Krasnik, et al.
British Journal of Cancer
|
July 1, 2010
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
U Lassen, L R Molife, M Sorensen, et al.
Investigational New Drugs
|
April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C Even, U Lassen, J Merchan, et al.
Cancer Chemotherapy and Pharmacology
|
December 1, 2012
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours
U Lassen, W H Miller, S Hotte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
C Massard, A Azaro, J-C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2025
Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting
L Belcaid, M Højgaard, I Tuxen, et al.
ESMO Open
|
November 6, 2025
A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium
S F Haj Mohammad, H van der Pol, E Vrdoljak, et al.
ESMO Open
|
May 13, 2026
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors
U Lassen, E M J van Brummelen, I Melero, et al.
Page
of 3